Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Adlai Nortye

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Oct 04, 2022 6:21pm

222 Views

Post# 35005398

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Adlai Nortye

In re AN. After thinking about this, it is quite possible that AN is not continuing with pela. They did sort of imply that in that email response. If that speculation is correct, I am not alarmed yet as it could mean a development. It was never very clear what AN was doing, as they did seem to be working at cross purposes; that is to say ONC did not seem to know what their game plan was. Hopefully some clarity soon. Cheers.

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism